KRAS mutation (any)

Activating KRAS mutations (codons 12, 13, 61 and others) detected by sequencing or PCR; used as a predictive marker, including as a negative predictor of response to anti-EGFR antibodies in colorectal cancer.

CI-BIO-00000016KRAS graph →NCIt C41361 Tumor-agnostic · 4 approval rows

Also calledKRAS-mutant · KRAS-mutated · RAS mutation

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug in derived setRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug in derived setRegulatory approved
Trametinib US FDA · May 29, 2013 · drug in derived setRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (26)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	95	89	6	—	4 / 35 / 25 / 31 / 0
Lung Non-Small Cell Carcinoma	31	25	5	1	2 / 24 / 1 / 3 / 1
Multiple Myeloma	17	13	4

Derived

Drugs with predictive evidence (57)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
CetuximabMonoclonal Antibody	47	6	41	A	5 / 39	Malignant Colorectal Neoplasm, Malignant Ovarian Neoplasm
PanitumumabMonoclonal Antibody	21	1	20	A	1 / 19	Colon Mucinous Adenocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	19	18	1	A	14 / 1	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm
MelphalanSmall Molecule	13	—	13	B	0 / 13	Multiple Myeloma
ErlotinibSmall Molecule	11	3	8	B	1 / 7	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Pancreatic Neoplasm +1
Chemotherapy	10	—	10	B	0 / 9	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	9	—	9	B	0 / 9	Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Lung Neoplasm
Regorafenib AnhydrousSmall Molecule	9	1	8	B	0 / 7	Malignant Colorectal Neoplasm
DocetaxelSmall Molecule	8	7	1	A	5 / 1	Cutaneous Melanoma, Lung Non-Small Cell Carcinoma
TrametinibSmall Molecule	8	7	1	B	5 / 1	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Malignant Neoplasm, Pancreatic Adenocarcinoma
DactolisibSmall Molecule	7	7	—	D	7 / 0	Lung Adenocarcinoma, Malignant Colorectal Neoplasm
VemurafenibSmall Molecule	5	1	4	B	0 / 4	Hairy Cell Leukemia, Malignant Colorectal Neoplasm, Melanoma
AfatinibSmall Molecule	4	4	—	C	4 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm, Pancreatic Ductal Adenocarcinoma
IrinotecanSmall Molecule	4	1	3	B	1 / 2	Malignant Colorectal Neoplasm
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor	3	2	1	B	2 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm
AbemaciclibSmall Molecule	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma
AdagrasibSmall Molecule	2	2	—	A	2 / 0	Malignant Colorectal Neoplasm, Solid Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm, Malignant Ovarian Serous Tumor
B-Raf/VEGFR-2 Inhibitor RAF265	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
CarboplatinSmall Molecule	2	1	1	B	1 / 1	Cutaneous Melanoma, Ovarian Carcinoma
DabrafenibSmall Molecule	2	—	2	B	0 / 2	Lung Adenocarcinoma, Melanoma
GemcitabineSmall Molecule	2	—	2	B	0 / 2	Malignant Pancreatic Neoplasm, Pancreatic Adenocarcinoma
PalbociclibSmall Molecule	2	2	—	D	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
SorafenibSmall Molecule	2	2	—	B	2 / 0	Cutaneous Melanoma, Hepatocellular Carcinoma
SotorasibSmall Molecule	2	2	—	A	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
TeprotumumabMonoclonal Antibody	2	2	—	B	2 / 0	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	—	2	B	0 / 1	Malignant Colorectal Neoplasm
CrizotinibSmall Molecule	2	1	1	C	1 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm
RefametinibSmall Molecule	2	2	—	B	1 / 0	Hepatocellular Carcinoma, Malignant Colorectal Neoplasm
MEK Inhibitor RO4987655	2	1	1	B	—	Lung Non-Small Cell Carcinoma, Malignant Colorectal Neoplasm
Akt Inhibitor MK2206	1	1	—	C	1 / 0	Pancreatic Carcinoma
ARS-853	1	1	—	D	1 / 0	Malignant Neoplasm
AtezolizumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
AZD5438	1	1	—	D	1 / 0	Malignant Neoplasm
Cetuximab/Irinotecan Regimen	1	—	1	C	0 / 1	Malignant Colorectal Neoplasm
CisplatinSmall Molecule	1	—	1	B	0 / 1	Head and Neck Squamous Cell Carcinoma
DasatinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
DecitabineSmall Molecule	1	1	—	D	1 / 0	Malignant Ovarian Neoplasm
DivarasibSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
G-573	1	1	—	D	1 / 0	Malignant Neoplasm
Immune Checkpoint Inhibitor	1	1	—	E	1 / 0	Lung Non-Small Cell Carcinoma
Immunomodulatory Oligonucleotide	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
IxazomibSmall Molecule	1	—	1	D	0 / 1	Malignant Colorectal Neoplasm
MEK Inhibitor GDC-0623	1	1	—	D	1 / 0	Malignant Neoplasm
NivolumabMonoclonal Antibody	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PaclitaxelSmall Molecule	1	—	1	B	0 / 1	Ovarian Carcinoma
PemetrexedSmall Molecule	1	1	—	B	1 / 0	Lung Non-Small Cell Carcinoma
PI3Kbeta Inhibitor AZD8186	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
PictilisibSmall Molecule	1	—	1	D	0 / 1	Malignant Breast Neoplasm
SCH772984Small Molecule	1	1	—	D	1 / 0	Pancreatic Adenocarcinoma
SirolimusSmall Molecule	1	1	—	D	1 / 0	Lung Adenocarcinoma
Therapeutic Tumor Infiltrating Lymphocytes	1	1	—	C	1 / 0	Malignant Colorectal Neoplasm
OxaliplatinSmall Molecule	1	—	1	B	—	Malignant Colorectal Neoplasm
RidaforolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm
SalirasibSmall Molecule	1	1	—	B	—	Lung Adenocarcinoma
TemsirolimusSmall Molecule	1	1	—	B	—	Malignant Endometrial Neoplasm

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (167)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 167 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
KRAS Q22*1
Panitumumab	Colon Mucinous Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID1131 A 43-year-old female was diagnosed with an adenocarcinoma of the ascending colon and received 6-months of adjuvant chemotherapy. After 5 years of completion of adjuvant chemotherapy, the disease relap… (full text at CIViC) PMID 19661358 · Palmirotta et al., 2009 · Open in CIViC	civic
KRAS Amplification1
Carboplatin + Docetaxel + SorafenibCombination	Cutaneous MelanomaALIAS	Predictive	B	Supports Sensitivity Response	2	accepted	EID1497 Retrospective analysis of somatic mutations and copy number changes in 119 patients treated with carboplatin, paclitaxel, ± sorafenib (CPS) in the E2603 trial. CPS therapy was associated with improved… (full text at CIViC) PMID 26307133 · Wilson et al., 2016 · Open in CIViC	civic
KRAS G12D4
Vemurafenib	Hairy Cell Leukemia	Predictive	C	Supports Resistance	2	accepted	EID1580 One patient enrolled in a clinical study to evaluate vemurafenib treatment of BRAF V600E mutant hairy-cell leukemia developed resistance to vemurafenib retreatment. 300-gene targeted sequencing of the… (full text at CIViC) PMID 26352686 · Tiacci et al., 2015 · Open in CIViC	civic
Dabrafenib	Lung Adenocarcinoma	Predictive	C	Supports Resistance	2	accepted	EID91 A 63 year old patient was diagnosed with lung adenocarcinoma and received several treatment regimens over approximately three years, including carboplatin/paclitaxel, erlotinib, pemetrexed/bevacizumab… (full text at CIViC) PMID 23524406 · Rudin et al., 2013 · Open in CIViC	civic
Dactolisib + SelumetinibCombination	Lung Adenocarcinoma	Predictive	D	Supports
KRAS RS617643701
Cisplatin	Head and Neck Squamous Cell Carcinoma	Predictive	B	Supports Resistance	3	accepted	EID872 In the retrospective analysis of 103 HNSSC, the TG/GG rs61764370 variant was associated with poor response to cisplatin (log-rank P = 0.002).There seemed to be some improvement when cetuximab was adde… (full text at CIViC) PMID 25081901 · Chung et al., 2014 · Open in CIViC	civic
KRAS Mutation23
Refametinib + SorafenibCombination	Hepatocellular Carcinoma	Predictive	B	Supports Sensitivity Response	2	accepted	EID1642 Phase 2 study in Asian patients with unresectable hepatocellular carcinoma. 70 patients received refametinib (BAY 86-9766) plus sorafenib as study treatment. A retrospective biomarker analysis was per… (full text at CIViC) PMID 25294897 · Lim et al., 2014 · Open in CIViC	civic
Salirasib	Lung Adenocarcinoma	Predictive	B	Does Not Support Sensitivity Response	3	accepted	EID1218 In a study of 30 lung adenocarcinoma patients with documented KRAS mutations, farnesylthiosalicylic acid (Salirasib) mono-therapy resulted in no partial responses and did not improve overall survival … (full text at CIViC) PMID 21847063 · Riely et al., 2011 · Open in CIViC	civic
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER
KRAS G12A1
Erlotinib + GefitinibSubstitutes	Lung Adenocarcinoma	Predictive	B	Supports Resistance	3	accepted	EID251 KRAS mutations (N=29 G12, N=1 G13) were the primary predictor of EGFR TKI resistance in patients with lung adenocarcinoma (N=83). Overall survival (P=0.001) and progression-free survival (P=0.005) wer… (full text at CIViC) PMID 19794967 · Marchetti et al., 2009 · Open in CIViC	civic
KRAS G12D + TSC1 Loss-of-functionKRAS TSC11
Sirolimus	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	3	accepted	EID154 Following rapamycin treatment of mice with KrasG12D-induced lung adenocarcinomas, mice with Tsc1 deletion (exon17/18 deletion resulting in frameshift) in the lung exhibit increased overall survival, i… (full text at CIViC) PMID 19966866 · Liang et al., 2010 · Open in CIViC	civic
KRAS A146V1
Abemaciclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	C	Supports Sensitivity Response	2	accepted	EID794 Case report of a patient with metastatic lung adenocarcinoma. Whole exome sequencing of the metastatic tumor revealed KRAS A146V, STK11 frameshift deletion and ATM alteration. Preclinical evidence led… (full text at CIViC) PMID 24836576 · Van Allen et al., 2014 · Open in CIViC	civic
KRAS G12C4
Divarasib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID11652 A phase 1 clinical study conducted with Divarasib in a total of 137 patients, of which 60 patients had NSCLC with G12C mutation in the KRAS gene. Confirmed response was noted in 53.4% (95% CI; 39.9 to… (full text at CIViC) PMID 37611121 · Sacher et al., 2023 · Open in CIViC	civic
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	2	accepted	EID1142 83 patients from a phase II trial (docetaxel + placebo or MEK1/2 inhibitor selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size a… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Sotorasib
KRAS G12V3
Docetaxel + SelumetinibCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	1	accepted	EID1143 83 patients from a phase II trial (docetaxel + placebo or selumetinib) with KRAS mutant tumors were retrospectively assessed for differences in OS, PFS, ORR and change in tumor size at week 6 accordin… (full text at CIViC) PMID 26125448 · Jänne et al., 2015 · Open in CIViC	civic
Palbociclib	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	D	Supports Sensitivity Response	1	accepted	EID795 In vivo studies confirmed the activity of PD0332991 (CDK4 inhibitor) on KRAS G12V mutant tumors. 17% (2/12) of mice treated with PD0332991 developed detectable lesions, whereas 75% of mice (3/4) treat… (full text at CIViC) PMID 20609353 · Puyol et al., 2010 · Open in CIViC	civic
Cetuximab
KRAS G12/G132
Erlotinib + GefitinibSubstitutes	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID35 In 60 patients with NSCLC, Exon 2 KRAS mutations were associated with resistance to the EGFR kinase inhibitors gefitinib or erlotinib (9/38 refractory vs 0/21 sensitive patients; P=0.0201). PMID 15696205 · Pao et al., 2005 · Open in CIViC	civic
Bevacizumab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Does Not Support Resistance	3	accepted	EID6295 This was a retrospective clinical study of 97 metastatic colorectal cancer patients who received bevacizumab in conjunction with first-line chemotherapy (composed of 5-fluorouracil (5-FU) only, 5-FU +… (full text at CIViC) PMID 19603024 · Souglakos et al., 2009 · Open in CIViC	civic
KRAS G13D6
Pictilisib	Malignant Breast Neoplasm	Predictive	D	Supports Resistance	4	accepted	EID2041 This preclinical study tested the efficacy on several breast cancer cell lines of GDC-0941 (pictilisib), a selective inhibitor of all four isoforms of class I PI3-kinases over a range of IC50 values. … (full text at CIViC) PMID 20453058 · O'Brien et al., 2010 · Open in CIViC	civic
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	accepted	EID306 KRAS G13D mutation is associated with better response to Cetuximab with longer progression-free and overall survival in colorectal patients compared to other KRAS. PMID 20978259 · De Roock et al., 2010 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B
KRAS Exon 2 Mutation2
Cetuximab	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	A	Supports Resistance	5	accepted	EID993 KRAS mutation status was assessed in 394 tumor samples from colorectal cancer patients who were randomly assigned to receive cetuximab plus best supportive care or best supportive care alone. 42% of… (full text at CIViC) PMID 18946061 · Karapetis et al., 2008 · Open in CIViC	civic
〃	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Resistance	3	accepted	EID250 Patients with colorectal cancer who harbor KRAS mutation have low response rate to cetuximab. PMID 16618717 · Lièvre et al., 2006 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (500)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

health-canada-dpdRegulatory50 approval records · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Docetaxel	CA Health Canada	—	Marketed in Canada as DOCETAXEL INJECTION USP (DIN 02361957) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Mar 1, 2011	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177080) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 31, 2020	Dec 31, 1995	health-canada-dpd
Docetaxel	CA Health Canada	—	Marketed in Canada as TAXOTERE (DIN 02177099) under ATC L01CD02 DOCETAXEL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.

Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (1,651)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 795 recruiting · 365 active phase 3 · 7,948 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 1–50 of 1,651 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02883062	Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer	active not recruiting	Phase 2	67	National Cancer Institute (NCI)NIH	1	Sep 30, 2026	clinicaltrials
NCT03257033	Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC(TIGeR-PaC)	active not recruiting	Phase 3	190	RenovoRxINDUSTRY	2	Sep 30, 2026	clinicaltrials
NCT04267848	Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])	recruiting	Phase 3	1,210	National Cancer Institute (NCI)NIH	2	Sep 30, 2026	clinicaltrials
NCT04570423	A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy	recruiting	Phase 2	40	Spectrum Pharmaceuticals, IncINDUSTRY	1	Sep 30, 2026	clinicaltrials
NCT04585490	Adaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC	recruiting	Phase 3	48	Stanford UniversityOTHER	1	Sep 30, 2026	clinicaltrials
NCT04835805	A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma.	active not recruiting	Phase 1	65	Genentech, Inc.INDUSTRY	5	Sep 30, 2026	clinicaltrials
NCT05047250	A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer	active not recruiting	Phase 3	60	Hoffmann-La RocheINDUSTRY	1	Sep 30, 2026	clinicaltrials
NCT05382559	A Study of ASP3082 in Adults With Advanced Solid Tumors	recruiting	Phase 1	681	Astellas Pharma IncINDUSTRY	7	Sep 30, 2026	clinicaltrials
NCT05525858	KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II(KOSMOSII)	active not recruiting	—	1,000	Seoul National University Bundang HospitalOTHER	1	Sep 30, 2026	clinicaltrials
NCT06081673	Penpulimab Combined With Chemotherapy for Neoadjuvant and Adjuvant Therapy in Patients With Resectable HNSCC	active not recruiting	Phase 2	72	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER	1	Sep 30, 2026	clinicaltrials
NCT06096844	Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial	recruiting	Phase 3	304	National Cancer Institute (NCI)NIH	1	Sep 30, 2026	clinicaltrials
NCT06219941	AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2	recruiting	Phase 2	226	AstraZenecaINDUSTRY	14	Sep 30, 2026	clinicaltrials
NCT06423326	Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic Cancer	recruiting	Phase 2	36	Georgetown UniversityOTHER	1	Sep 30, 2026	clinicaltrials
NCT06589804	Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment	recruiting	Phase 3	158	National Cancer Institute (NCI)NIH	1	Sep 30, 2026	clinicaltrials
NCT06806852	A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone	active not recruiting	Phase 1	91	Boehringer IngelheimINDUSTRY	22	Sep 30, 2026	clinicaltrials
NCT07278336	A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Other Anticancer Drugs in Adult Participants With Ovarian Cancer	recruiting	Phase 1	285	AbbVieINDUSTRY	7	Sep 30, 2026	clinicaltrials
NCT07491445	Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma(RASolute 303)	recruiting	Phase 3	900	Revolution Medicines, Inc.INDUSTRY	12	Sep 30, 2026	clinicaltrials
NCT02446600	Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	active not recruiting	Phase 3	579	National Cancer Institute (NCI)NIH	4	Sep 29, 2026	clinicaltrials
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	active not recruiting	Phase 2	6,452	National Cancer Institute (NCI)NIH	3	Sep 29, 2026	clinicaltrials
NCT02502266	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	active not recruiting	Phase 2 / Phase 3	582	National Cancer Institute (NCI)NIH	5	Sep 29, 2026	clinicaltrials
NCT02595944	Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial)(ANVIL)	active not recruiting	Phase 3	903	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT03707808	Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, AS01B, and Ipilimumab Plus Systemic Nivolumab(myDAvIpNi)	active not recruiting	Phase 1 / Phase 2	18	Universitair Ziekenhuis BrusselOTHER	1	Sep 29, 2026	clinicaltrials
NCT03793179	Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer	active not recruiting	Phase 3	600	National Cancer Institute (NCI)NIH	3	Sep 29, 2026	clinicaltrials
NCT04111458	A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)	active not recruiting	Phase 1	71	Boehringer IngelheimINDUSTRY	3	Sep 29, 2026	clinicaltrials
NCT04175912	Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver	active not recruiting	Phase 2	40	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT04181060	Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer	recruiting	Phase 3	300	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT04310007	Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer	active not recruiting	Phase 2	117	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT04396821	A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1 / Phase 2	150	Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY	1	Sep 29, 2026	clinicaltrials
NCT04495296	A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors	active not recruiting	Phase 1 / Phase 2	320	Transcenta Therapeutics (Hangzhou) Co., Ltd.INDUSTRY	1	Sep 29, 2026	clinicaltrials
NCT05564377	Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial	recruiting	Phase 2	2,900	National Cancer Institute (NCI)NIH	2	Sep 29, 2026	clinicaltrials
NCT05611034	In Vivo Lung Perfusion (IVLP) for Colorectal Cancer Metastatic to Lung	recruiting	Phase 1	10	University Health Network, TorontoOTHER	1	Sep 29, 2026	clinicaltrials
NCT05891171	Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers(ARC-25)	active not recruiting	Phase 1	40	Arcus Biosciences, Inc.INDUSTRY	3	Sep 29, 2026	clinicaltrials
NCT06448754	Volrustomig Priming Regimens Exploratory Phase II Platform Study(eVOLVE-01)	active not recruiting	Phase 2	194	AstraZenecaINDUSTRY	14	Sep 29, 2026	clinicaltrials
NCT06608927	Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(PRISM-1)	active not recruiting	Phase 3	610	Arcus Biosciences, Inc.INDUSTRY	13	Sep 29, 2026	clinicaltrials
NCT06772623	Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations	recruiting	Phase 1 / Phase 2	252	AbbVieINDUSTRY	15	Sep 29, 2026	clinicaltrials
NCT06881784	Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)(RASolve 301)	recruiting	Phase 3	590	Revolution Medicines, Inc.INDUSTRY	19	Sep 29, 2026	clinicaltrials
NCT06890338	A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.	recruiting	Phase 2	140	AbbVieINDUSTRY	1	Sep 29, 2026	clinicaltrials
NCT07030959	Study of AUBE00 in Patients With Solid Tumors	recruiting	Phase 1	130	Chugai PharmaceuticalINDUSTRY	2	Sep 29, 2026	clinicaltrials
NCT07361484	Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)	not yet recruiting	Phase 3	442	BeyondSpring Pharmaceuticals Inc.INDUSTRY	0	Sep 29, 2026	clinicaltrials
NCT07388524	Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial	recruiting	Phase 3	336	National Cancer Institute (NCI)NIH	1	Sep 29, 2026	clinicaltrials
NCT07659795	A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Colorectal Cancer(TARGET-D 203)	recruiting	Phase 2	150	Verastem, Inc.INDUSTRY	2	Sep 29, 2026	clinicaltrials
NCT07744126	A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma	recruiting	Phase 2	150	AbbVieINDUSTRY	2	Sep 29, 2026	clinicaltrials
NCT07845786	Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)(STELLAR-202)	not yet recruiting	Phase 2	60	ExelixisINDUSTRY	0	Sep 29, 2026	clinicaltrials
NCT07846358	This is a Multicenter, Open-label, Phase I/II Study to Explore the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of GFH276 in Patients With Advanced NSCLC Harboring a RAS Mutation.(GFH276X1203)	not yet recruiting	Phase 1 / Phase 2	84	Genfleet Therapeutics (Shanghai) Inc.INDUSTRY	0	Sep 29, 2026	clinicaltrials
NCT00092222	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity	active not recruiting	Phase 2	75	National Cancer Institute (NCI)NIH	1	Sep 28, 2026	clinicaltrials
NCT04793958	Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)	active not recruiting	Phase 3	461	Mirati Therapeutics Inc.INDUSTRY	32	Sep 28, 2026	clinicaltrials
NCT04988295	A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure(MARIPOSA-2)	active not recruiting	Phase 3	776	Janssen Research & Development, LLCINDUSTRY	29	Sep 28, 2026	clinicaltrials
NCT05482893	Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study)	recruiting	Phase 1 / Phase 2	350	Phanes TherapeuticsINDUSTRY	1	Sep 28, 2026	clinicaltrials
NCT05498428	A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer(PALOMA-2)	recruiting	Phase 2	520	Janssen Research & Development, LLCINDUSTRY	12	Sep 28, 2026	clinicaltrials
NCT05867251	Study of AVZO-021 in Patients With Advanced Solid Tumors	recruiting	Phase 1 / Phase 2	430	Avenzo Therapeutics, Inc.INDUSTRY	2	Sep 28, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (26)

Drugs with predictive evidence (57)

Predictive evidence items (167)

Approvals mentioning the linked drugs (500)

Active trials (1,651)

Linked publications (113)